All In Biotech

Drug Trial Radar · NCT00949351

Safety of Add on Aliskiren to Angiotensin Converting Enzyme Inhibitor (ACEI) and Angiotensin I Receptor Blocker (ARB) Treatment in Type 2 Diabetes With Nephropathy

Safety of Add on Aliskiren to ACEI and ARB Treatment in Type 2 Diabetes With Nephropathy

Last checked: Nov 20, 2026Latest source record: Jul 30, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

80

Planned (sponsor's estimate)

Start

Sep 2009

Primary completion

Jul 2010

Study completion Sep 2010

Sponsor

Lead sponsor
Lerdsin General HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 30, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 30 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Activation of renin-angiotensin plays a crucial role diabetic nephropathy. Angiotensin converting enzyme inhibitor (ACEI) and Angiotensin I receptor blocker (ARB) has been shown renoprotection whether it was used alone or in combination. Aliskiren is a direct renin inhibitor (DRI) that has shown renal benefits and safety when combined with ARB. However, to date, the safety of add on aliskiren to the combination treatment of ACEI and ARB in diabetic nephropathy patients remains to elucidate.

Conditions

  • Type 2 Diabetes With Nephropathy

Interventions

  • Aliskiren 300mg/dDrug

    Aliskiren 300mg/d v.s. placebo for 12wk

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assess short-term safety of the combination of aliskiren 300 mg/valsartan 160 mg /enalapril 20 mg in patients with diabetic nephropathyTime frame: 12 wk after randomization

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Lerdsin General Hospital

    Bangkok, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.